Ebola

Featured Article

Ebola Vaccine Long-Term Safety and Antibody Response

Ebola Vaccine Long-Term Safety and Antibody Response

An Ebola virus vaccine, rVSVΔG-ZEBOV-GP, provided 100% protection against Ebola in a prior phase 3 trial. A new study reports long-term safety data and shows that the vaccine induces an antibody response for at least 1 year.

Latest News

Evidence-Based Guidelines for Supportive Care in Ebola Treatment

Evidence-Based Guidelines for Supportive Care in Ebola Treatment

First-hand accounts of the care that was delivered during the 2013-16 West African outbreak of Ebola virus disease provided impetus for these guidelines.

Two Preclinical Ebola Vaccines Elicit Sustained Immune Responses

Two Preclinical Ebola Vaccines Elicit Sustained Immune Responses

Two vaccines to prevent Ebola virus disease demonstrated immune responses at 1 month.

Novel Retinal Abnormality Seen in Ebola Survivors

Novel Retinal Abnormality Seen in Ebola Survivors

A small percentage of Ebola virus survivors have a novel retinal lesion as a result of the disease.

Ebola Outbreak: What to Consider if Experimental Vaccine Is Used

Ebola Outbreak: What to Consider if Experimental Vaccine Is Used

The number of suspected Ebola cases in the Democratic Republic of Congo has risen to 37.

Immunity Persists for Ebola Vaccines at One Year

Immunity Persists for Ebola Vaccines at One Year

A strategy of preemptive use of an AD26.ZEBOV followed by MVA-BN-Filo immunization schedule in at-risk populations may offer advantages over reactive use of single-dose vaccine regimens.

Blood Test May Determine Chance of Surviving Ebola Infection

Blood Test May Determine Chance of Surviving Ebola Infection

Changes in messenger RNA abundance proved to be a reliable means of predicting patient's chances of surviving Ebola virus disease.

New Ebola Vaccine Highly Effective in Preventing Spread of Disease

New Ebola Vaccine Highly Effective in Preventing Spread of Disease

A new vaccine for Ebola showed high efficacy in preventing the development of Ebola in clusters of people exposed to the virus, and protection was also conferred to those who were not vaccinated.

Despite Challenges, Liberia's Semen Screening Program for Ebola Successful

Despite Challenges, Liberia's Semen Screening Program for Ebola Successful

Liberia's Men's Health Screening Program for Ebola survivors successful in spite of complex challenges.

CDC Official Emphasizes Prevention as Data Show Ebola Virus Lingers in Semen

CDC Official Emphasizes Prevention as Data Show Ebola Virus Lingers in Semen

Virus is more likely to be found in male survivors older than 40, researchers report.

Investigational Ebola Vaccine Gets 'Breakthrough Therapy' Designation by FDA

Investigational Ebola Vaccine Gets 'Breakthrough Therapy' Designation by FDA

The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of a candidate vaccine that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition.

Sign Up for Free e-newsletters